source
- Rising Hospital and Drug Prices Drive Up Insurance Premiums for Workers and EmployersBob Herman’s investigation, based on interviews with more than twenty health policy experts and industry leaders, finds that soaring hospital and pharmaceutical prices are the primary force behind…
- CSL agrees $355M upfront deal to co-develop Alentis anti-fibrosis drug for kidney and liverCSL, an Australian drugmaker, announced a partnership with Alentis Therapeutics that includes a $355 million upfront payment. Under the agreement, CSL will co-develop Alentis's anti-fibrosis candi…